{"success":true,"data":{"pressRelease":{"id":"69578","rtpr_id":"nBw73PYvHa","ticker":"DHR","exchange":"NYSE","all_tickers":["DHR"],"title":"Masimo Receives FDA 510(k) Clearance for AI-Enabled Opioid-Induced Respiratory Depression (OIRD) Detection on Radius VSM® to Help Identify Respiratory Risk Sooner","author":"Business Wire","published_at":"2026-06-22T12:00:00.632Z","article_body":"Masimo Receives FDA 510(k) Clearance for AI-Enabled Opioid-Induced Respiratory\nDepression (OIRD) Detection on Radius VSM(®) to Help Identify Respiratory\nRisk Sooner\n\nPowered by smartSET™, the Pattern Recognition Capability Analyzes Continuous\nPatient Data to Provide Clinicians With Earlier Insight Into Opioid-Related\nRespiratory Risk\n\nMasimo\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.masimo.com&esheet=54557158&newsitemid=20260622460376&lan=en-US&anchor=Masimo&index=1&md5=3ccacd4355b1e995bf0e8c89a769e9fc)\n, a Danaher company and a specialty diagnostics solutions innovator of pulse\noximetry and other patient monitoring solutions, today announced FDA 510(k)\nclearance for an opioid-induced respiratory depression detection capability\nintegrated into the Radius VSM(®) wearable continuous patient monitor.\nEnabled by Masimo’s next-generation smartSET™ pulse oximetry sensor\nplatform, the new feature uses advanced pattern recognition that analyzes\ncontinuous physiologic data to help clinicians identify early signs of\nrespiratory compromise in hospital patients receiving opioid therapy.\n\nThis press release features multimedia. View the full release here:\nhttps://www.businesswire.com/news/home/20260622460376/en/\n(https://www.businesswire.com/news/home/20260622460376/en/)\n\nOpioid-Induced Respiratory Depression Detection with Masimo smartSET™ and\nRadius VSM®\n\nThis clearance represents the first implementation of Masimo’s OIRD\ndetection capability in a hospital monitoring solution. By combining the\ntrusted signal quality of best-in-class Masimo SET(®) with AI-enabled\nanalysis, smartSET features like OIRD detection are expanding the role of\npulse oximetry from monitoring patient status to surfacing actionable\ninsights. Translating continuous data into earlier clinical awareness supports\nfaster, more informed decisions when time matters most, such as when a\npatient’s condition is rapidly worsening. To accelerate the potential impact\nof such technology on how patient care is delivered throughout the hospital,\nMasimo is developing additional pattern-recognition algorithms for the\nsmartSET platform.\n\n“Opioid-Induced Respiratory Depression remains a critical patient-safety\nconcern,” said Dr. Basil Matta, Chief Medical Officer at Masimo. “With\nOIRD detection, Masimo is bringing advanced pattern recognition to continuous,\nwearable monitoring to help clinicians identify earlier changes in a\npatient’s respiratory status that may not be apparent through traditional\napproaches. This capability reflects our ongoing focus on working closely with\nclinicians to address complex patient-safety challenges with meaningful\ninnovation. OIRD detection on Radius VSM will help expand continuous\nmonitoring from simple measurement to meaningful insight, supporting safer\ncare throughout the hospital.”\n\nBuilding on industry-leading RD SET(®) sensor technology, smartSET is\nengineered to unlock the value of continuous parameter insights by analyzing\ncomplex physiological patterns and relationships rather than relying on\nindividual parameters alone. Its design also allows for future integration\ninto additional hospital monitoring solutions, extending its transformative\nimpact across care environments as part of Masimo’s broader connected\necosystem.\n\nRadius VSM is a wearable, tetherless, modular vital signs monitor designed to\nsupport continuous assessment of patient status throughout the hospital, with\nthe ability to tailor monitoring to meet each patient’s needs. The addition\nof smartSET-powered analysis and OIRD detection to Radius VSM expands the\nplatform’s ability to assist clinicians in spotting changes in patient\ncondition and helps bring advanced physiological insight to more care areas.\nThe OIRD feature includes visual alarms, which alert clinicians to changes in\na patient’s condition and escalate as OIRD risk increases. The alarms are\npresented on the device’s display and can be relayed to remote and\ncentralized monitoring stations.\n\n@Masimo\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.twitter.com%2FMasimo&esheet=54557158&newsitemid=20260622460376&lan=en-US&anchor=%40Masimo&index=2&md5=070d93f654a3b93ce144abf36aa2214d)\n| #Masimo\n\nAbout Masimo\n\nMasimo, a Danaher company and a specialty diagnostics solutions innovator of\npulse oximetry and other patient monitoring solutions, develops and produces a\nwide array of industry-leading monitoring technologies, including innovative\nmeasurements, sensors, patient monitors, and automation and connectivity\nsolutions. Our mission is for our innovations to empower clinicians to\ntransform patient care. Masimo SET(®) Measure-through Motion and Low\nPerfusion™ pulse oximetry, introduced in 1995, has been shown to outperform\nother pulse oximetry technologies in over 100 independent and objective\nstudies, which can be found at\nwww.masimo.com/evidence/featured-studies/feature\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.masimo.com%2Fevidence%2Ffeatured-studies%2Ffeature&esheet=54557158&newsitemid=20260622460376&lan=en-US&anchor=www.masimo.com%2Fevidence%2Ffeatured-studies%2Ffeature&index=3&md5=c6790887722d2fdae60d49ab15f64ac6)\n. Masimo SET(®) is estimated to be used on more than 200 million patients\naround the world each year and is the primary pulse oximetry at all 10 top\nU.S. hospitals as ranked in the 2026 Newsweek World’s Best Hospitals\nlisting. Additional information about Masimo and its products may be found at\nwww.masimo.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.masimo.com%2F&esheet=54557158&newsitemid=20260622460376&lan=en-US&anchor=www.masimo.com&index=4&md5=7acec18b383658c43e027c96b3615f16)\n.\n\nAbout Danaher\n\nDanaher is a leading global life sciences and diagnostics innovator, committed\nto accelerating the power of science and technology to improve human health.\nThrough our connected ecosystem of industry-leading businesses, we work side\nby side with customers to solve their most complex scientific and clinical\nchallenges—helping move innovations from discovery to delivery faster for\npatients who depend on them. Powered by the Danaher Business System, our\nadvanced science and technology and proven ability to innovate help enable\nfaster, more accurate diagnoses and reduce the time, cost, and risk required\nto discover, develop, and deliver life-changing therapies. Through continuous\nimprovement and operational excellence, our approximately 60,000 associates\nworldwide are focused on delivering lasting impact and improving quality of\nlife around the world, while building a healthier, more sustainable tomorrow.\nExplore more at www.danaher.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4258988-1%26h%3D1914481706%26u%3Dhttps%253A%252F%252Fwww.danaher.com%252F%26a%3Dwww.danaher.com&esheet=54557158&newsitemid=20260622460376&lan=en-US&anchor=www.danaher.com&index=5&md5=a3f96891e21c2ec1de2c8ad7241aacfc)\n.\n\nForward-Looking Statements and Other Information\n\nStatements in this release that are not strictly historical, including the\nstatements regarding extending smartSET’s transformative impact across care\nenvironments, and any other statements regarding events or developments that\nwe believe or anticipate will or may occur in the future are \"forward-looking\"\nstatements within the meaning of the federal securities laws. There are a\nnumber of important factors that could cause Danaher Corporation’s and its\nsubsidiaries’ actual results, developments and business decisions to differ\nmaterially from those suggested or indicated by such forward-looking\nstatements and you should not place undue reliance on any such forward-looking\nstatements. These factors include, among other things: the impact of the\ntariffs and related actions implemented by the U.S. and other countries, the\nimpact of our debt obligations (including debt we have incurred to finance the\nacquisition of Masimo Corporation) on our operations and liquidity,\ndeterioration of or instability in the global economy, the markets we serve\nand the financial markets, uncertainties with respect to the development,\ndeployment, and use of artificial intelligence in our business and products,\nthe impact of global health crises, uncertainties relating to national laws or\npolicies, including laws or policies to protect or promote domestic interests\nand/or address foreign competition, our ability to successfully identify and\nconsummate appropriate acquisitions and strategic investments, our ability to\nintegrate the businesses we acquire and achieve the anticipated growth,\nsynergies and other benefits of such acquisitions, contingent liabilities and\nother risks relating to acquisitions, investments, strategic relationships and\ndivestitures (in each case, including with respect to our recent acquisition\nof Masimo Corporation), including tax-related and other contingent liabilities\nrelating to past and future IPOs, split-offs or spin-offs, contractions or\ngrowth rates and cyclicality of markets we serve, competition, our ability to\ndevelop and successfully market new products and technologies and expand into\nnew markets, the potential for improper conduct by our employees, agents or\nbusiness partners, our compliance with applicable laws and regulations\n(including rules relating to off-label marketing and other regulations\nrelating to medical devices and the health care industry), the results of our\nclinical trials and perceptions thereof, our ability to effectively address\ncost reductions and other changes in the health care industry, security\nbreaches or other disruptions of our information technology systems or\nviolations of data privacy laws, risks relating to potential impairment of\ngoodwill and other intangible assets, currency exchange rates, tax audits and\nchanges in our tax rate and income tax liabilities, changes in tax laws\napplicable to multinational companies, litigation, regulatory proceedings and\nother contingent liabilities including intellectual property and\nenvironmental, health and safety matters, the rights of the United States\ngovernment with respect to our production capacity in times of national\nemergency or with respect to intellectual property/production capacity\ndeveloped using government funding, risks relating to product, service or\nsoftware defects, product liability and recalls, risks relating to our\nmanufacturing operations, the impact of climate change, legal or regulatory\nmeasures to address climate change and other sustainability topics and our\nability to address regulatory requirements or stakeholder expectations\nrelating to climate change and other sustainability topics, risks relating to\nfluctuations in the cost and availability of the supplies we use (including\ncommodities) and labor we need for our operations, our relationships with and\nthe performance of our channel partners, uncertainties relating to\ncollaboration arrangements with third-parties, the impact of deregulation on\ndemand for our products and services, labor matters and our ability to\nrecruit, retain and motivate talented employees, U.S. and non-U.S. economic,\npolitical, geopolitical, legal, compliance, social and business factors\n(including the impact of elections, regulatory and policy changes or\nuncertainty, government shutdowns and military conflicts such as the conflict\nin the Middle East), disruptions and other impacts relating to man-made and\nnatural disasters, inflation and the impact of our By-law exclusive forum\nprovisions. Additional information regarding the factors that may cause actual\nresults to differ materially from these forward-looking statements is\navailable in Danaher Corporation’s SEC filings, including Danaher\nCorporation’s 2025 Annual Report on Form 10-K and Quarterly Report on Form\n10-Q for the first quarter of 2026. These forward-looking statements speak\nonly as of the date of this release and except to the extent required by\napplicable law, Danaher Corporation does not assume any obligation to update\nor revise any forward-looking statement, whether as a result of new\ninformation, future events and developments or otherwise.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260622460376/en/\n(https://www.businesswire.com/news/home/20260622460376/en/)\n\nMedia Contact: \n\nChristine McCullough\n\nchristine.mccullough@masimo.com (mailto:christine.mccullough@masimo.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw73PYvHa","title":"Masimo Receives FDA 510(k) Clearance for AI-Enabled Opioid-Induced Respiratory Depression (OIRD) Detection on Radius VSM® to Help Identify Respiratory Risk Sooner","author":"Business Wire","ticker":"DHR","created":"2026-06-22T12:00:00.632Z","tickers":["DHR"],"exchange":"NYSE","article_body":"Masimo Receives FDA 510(k) Clearance for AI-Enabled Opioid-Induced Respiratory\nDepression (OIRD) Detection on Radius VSM(®) to Help Identify Respiratory\nRisk Sooner\n\nPowered by smartSET™, the Pattern Recognition Capability Analyzes Continuous\nPatient Data to Provide Clinicians With Earlier Insight Into Opioid-Related\nRespiratory Risk\n\nMasimo\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.masimo.com&esheet=54557158&newsitemid=20260622460376&lan=en-US&anchor=Masimo&index=1&md5=3ccacd4355b1e995bf0e8c89a769e9fc)\n, a Danaher company and a specialty diagnostics solutions innovator of pulse\noximetry and other patient monitoring solutions, today announced FDA 510(k)\nclearance for an opioid-induced respiratory depression detection capability\nintegrated into the Radius VSM(®) wearable continuous patient monitor.\nEnabled by Masimo’s next-generation smartSET™ pulse oximetry sensor\nplatform, the new feature uses advanced pattern recognition that analyzes\ncontinuous physiologic data to help clinicians identify early signs of\nrespiratory compromise in hospital patients receiving opioid therapy.\n\nThis press release features multimedia. View the full release here:\nhttps://www.businesswire.com/news/home/20260622460376/en/\n(https://www.businesswire.com/news/home/20260622460376/en/)\n\nOpioid-Induced Respiratory Depression Detection with Masimo smartSET™ and\nRadius VSM®\n\nThis clearance represents the first implementation of Masimo’s OIRD\ndetection capability in a hospital monitoring solution. By combining the\ntrusted signal quality of best-in-class Masimo SET(®) with AI-enabled\nanalysis, smartSET features like OIRD detection are expanding the role of\npulse oximetry from monitoring patient status to surfacing actionable\ninsights. Translating continuous data into earlier clinical awareness supports\nfaster, more informed decisions when time matters most, such as when a\npatient’s condition is rapidly worsening. To accelerate the potential impact\nof such technology on how patient care is delivered throughout the hospital,\nMasimo is developing additional pattern-recognition algorithms for the\nsmartSET platform.\n\n“Opioid-Induced Respiratory Depression remains a critical patient-safety\nconcern,” said Dr. Basil Matta, Chief Medical Officer at Masimo. “With\nOIRD detection, Masimo is bringing advanced pattern recognition to continuous,\nwearable monitoring to help clinicians identify earlier changes in a\npatient’s respiratory status that may not be apparent through traditional\napproaches. This capability reflects our ongoing focus on working closely with\nclinicians to address complex patient-safety challenges with meaningful\ninnovation. OIRD detection on Radius VSM will help expand continuous\nmonitoring from simple measurement to meaningful insight, supporting safer\ncare throughout the hospital.”\n\nBuilding on industry-leading RD SET(®) sensor technology, smartSET is\nengineered to unlock the value of continuous parameter insights by analyzing\ncomplex physiological patterns and relationships rather than relying on\nindividual parameters alone. Its design also allows for future integration\ninto additional hospital monitoring solutions, extending its transformative\nimpact across care environments as part of Masimo’s broader connected\necosystem.\n\nRadius VSM is a wearable, tetherless, modular vital signs monitor designed to\nsupport continuous assessment of patient status throughout the hospital, with\nthe ability to tailor monitoring to meet each patient’s needs. The addition\nof smartSET-powered analysis and OIRD detection to Radius VSM expands the\nplatform’s ability to assist clinicians in spotting changes in patient\ncondition and helps bring advanced physiological insight to more care areas.\nThe OIRD feature includes visual alarms, which alert clinicians to changes in\na patient’s condition and escalate as OIRD risk increases. The alarms are\npresented on the device’s display and can be relayed to remote and\ncentralized monitoring stations.\n\n@Masimo\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.twitter.com%2FMasimo&esheet=54557158&newsitemid=20260622460376&lan=en-US&anchor=%40Masimo&index=2&md5=070d93f654a3b93ce144abf36aa2214d)\n| #Masimo\n\nAbout Masimo\n\nMasimo, a Danaher company and a specialty diagnostics solutions innovator of\npulse oximetry and other patient monitoring solutions, develops and produces a\nwide array of industry-leading monitoring technologies, including innovative\nmeasurements, sensors, patient monitors, and automation and connectivity\nsolutions. Our mission is for our innovations to empower clinicians to\ntransform patient care. Masimo SET(®) Measure-through Motion and Low\nPerfusion™ pulse oximetry, introduced in 1995, has been shown to outperform\nother pulse oximetry technologies in over 100 independent and objective\nstudies, which can be found at\nwww.masimo.com/evidence/featured-studies/feature\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.masimo.com%2Fevidence%2Ffeatured-studies%2Ffeature&esheet=54557158&newsitemid=20260622460376&lan=en-US&anchor=www.masimo.com%2Fevidence%2Ffeatured-studies%2Ffeature&index=3&md5=c6790887722d2fdae60d49ab15f64ac6)\n. Masimo SET(®) is estimated to be used on more than 200 million patients\naround the world each year and is the primary pulse oximetry at all 10 top\nU.S. hospitals as ranked in the 2026 Newsweek World’s Best Hospitals\nlisting. Additional information about Masimo and its products may be found at\nwww.masimo.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.masimo.com%2F&esheet=54557158&newsitemid=20260622460376&lan=en-US&anchor=www.masimo.com&index=4&md5=7acec18b383658c43e027c96b3615f16)\n.\n\nAbout Danaher\n\nDanaher is a leading global life sciences and diagnostics innovator, committed\nto accelerating the power of science and technology to improve human health.\nThrough our connected ecosystem of industry-leading businesses, we work side\nby side with customers to solve their most complex scientific and clinical\nchallenges—helping move innovations from discovery to delivery faster for\npatients who depend on them. Powered by the Danaher Business System, our\nadvanced science and technology and proven ability to innovate help enable\nfaster, more accurate diagnoses and reduce the time, cost, and risk required\nto discover, develop, and deliver life-changing therapies. Through continuous\nimprovement and operational excellence, our approximately 60,000 associates\nworldwide are focused on delivering lasting impact and improving quality of\nlife around the world, while building a healthier, more sustainable tomorrow.\nExplore more at www.danaher.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4258988-1%26h%3D1914481706%26u%3Dhttps%253A%252F%252Fwww.danaher.com%252F%26a%3Dwww.danaher.com&esheet=54557158&newsitemid=20260622460376&lan=en-US&anchor=www.danaher.com&index=5&md5=a3f96891e21c2ec1de2c8ad7241aacfc)\n.\n\nForward-Looking Statements and Other Information\n\nStatements in this release that are not strictly historical, including the\nstatements regarding extending smartSET’s transformative impact across care\nenvironments, and any other statements regarding events or developments that\nwe believe or anticipate will or may occur in the future are \"forward-looking\"\nstatements within the meaning of the federal securities laws. There are a\nnumber of important factors that could cause Danaher Corporation’s and its\nsubsidiaries’ actual results, developments and business decisions to differ\nmaterially from those suggested or indicated by such forward-looking\nstatements and you should not place undue reliance on any such forward-looking\nstatements. These factors include, among other things: the impact of the\ntariffs and related actions implemented by the U.S. and other countries, the\nimpact of our debt obligations (including debt we have incurred to finance the\nacquisition of Masimo Corporation) on our operations and liquidity,\ndeterioration of or instability in the global economy, the markets we serve\nand the financial markets, uncertainties with respect to the development,\ndeployment, and use of artificial intelligence in our business and products,\nthe impact of global health crises, uncertainties relating to national laws or\npolicies, including laws or policies to protect or promote domestic interests\nand/or address foreign competition, our ability to successfully identify and\nconsummate appropriate acquisitions and strategic investments, our ability to\nintegrate the businesses we acquire and achieve the anticipated growth,\nsynergies and other benefits of such acquisitions, contingent liabilities and\nother risks relating to acquisitions, investments, strategic relationships and\ndivestitures (in each case, including with respect to our recent acquisition\nof Masimo Corporation), including tax-related and other contingent liabilities\nrelating to past and future IPOs, split-offs or spin-offs, contractions or\ngrowth rates and cyclicality of markets we serve, competition, our ability to\ndevelop and successfully market new products and technologies and expand into\nnew markets, the potential for improper conduct by our employees, agents or\nbusiness partners, our compliance with applicable laws and regulations\n(including rules relating to off-label marketing and other regulations\nrelating to medical devices and the health care industry), the results of our\nclinical trials and perceptions thereof, our ability to effectively address\ncost reductions and other changes in the health care industry, security\nbreaches or other disruptions of our information technology systems or\nviolations of data privacy laws, risks relating to potential impairment of\ngoodwill and other intangible assets, currency exchange rates, tax audits and\nchanges in our tax rate and income tax liabilities, changes in tax laws\napplicable to multinational companies, litigation, regulatory proceedings and\nother contingent liabilities including intellectual property and\nenvironmental, health and safety matters, the rights of the United States\ngovernment with respect to our production capacity in times of national\nemergency or with respect to intellectual property/production capacity\ndeveloped using government funding, risks relating to product, service or\nsoftware defects, product liability and recalls, risks relating to our\nmanufacturing operations, the impact of climate change, legal or regulatory\nmeasures to address climate change and other sustainability topics and our\nability to address regulatory requirements or stakeholder expectations\nrelating to climate change and other sustainability topics, risks relating to\nfluctuations in the cost and availability of the supplies we use (including\ncommodities) and labor we need for our operations, our relationships with and\nthe performance of our channel partners, uncertainties relating to\ncollaboration arrangements with third-parties, the impact of deregulation on\ndemand for our products and services, labor matters and our ability to\nrecruit, retain and motivate talented employees, U.S. and non-U.S. economic,\npolitical, geopolitical, legal, compliance, social and business factors\n(including the impact of elections, regulatory and policy changes or\nuncertainty, government shutdowns and military conflicts such as the conflict\nin the Middle East), disruptions and other impacts relating to man-made and\nnatural disasters, inflation and the impact of our By-law exclusive forum\nprovisions. Additional information regarding the factors that may cause actual\nresults to differ materially from these forward-looking statements is\navailable in Danaher Corporation’s SEC filings, including Danaher\nCorporation’s 2025 Annual Report on Form 10-K and Quarterly Report on Form\n10-Q for the first quarter of 2026. These forward-looking statements speak\nonly as of the date of this release and except to the extent required by\napplicable law, Danaher Corporation does not assume any obligation to update\nor revise any forward-looking statement, whether as a result of new\ninformation, future events and developments or otherwise.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260622460376/en/\n(https://www.businesswire.com/news/home/20260622460376/en/)\n\nMedia Contact: \n\nChristine McCullough\n\nchristine.mccullough@masimo.com (mailto:christine.mccullough@masimo.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-06-22T12:00:01.498068723Z","server_sent_at_ms":1782129601498},"received_at":"2026-06-22T12:00:01.673Z","source_url":"https://www.businesswire.com/news/home/20260622460376/en/"},"analysis":{"id":"58973","press_release_id":"69578","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":[],"eventType":"product_launch","narrative":"Masimo, a subsidiary of Danaher, received FDA 510(k) clearance for an AI-enabled Opioid-Induced Respiratory Depression (OIRD) detection capability on its Radius VSM wearable monitor.\n\nThe feature, powered by the smartSET platform, uses advanced pattern recognition to analyze continuous patient data and provide earlier clinical insight.\n\nThis represents the first implementation of Masimo’s OIRD detection in a hospital monitoring solution, expanding the role of pulse oximetry to surfacing actionable insights.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Incremental FDA clearance for AI feature on existing platform; marginally enhances safety profile."},"keyFigures":{},"quotedText":"Opioid-Induced Respiratory Depression remains a critical patient-safety concern","namedEntities":{"people":[{"name":"Dr. Basil Matta","role":"Chief Medical Officer at Masimo"}],"products":["Radius VSM","smartSET","Masimo SET","RD SET"],"companies":[{"name":"Masimo","relationship":"subsidiary"},{"name":"Danaher","relationship":"parent company"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"FDA 510(k) clearance for an AI-enabled OIRD detection feature on an existing product (Radius VSM) is a positive advancement but incremental; not a binary new product approval (PMA) or revenue driver in itself. Enhances competitive positioning in patient monitoring."},"tickerRelevance":{"others":[],"primary":"DHR"},"globalImportance":30,"audienceRelevance":25,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mega-cap","eventGravity":"510k_clearance_feature","sectorWeight":"health_care_devices","marketCapAdjustment":-10}},"event_type":"product_launch","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"Masimo, a subsidiary of Danaher, received FDA 510(k) clearance for an AI-enabled Opioid-Induced Respiratory Depression (OIRD) detection capability on its Radius VSM wearable monitor.\n\nThe feature, powered by the smartSET platform, uses advanced pattern recognition to analyze continuous patient data and provide earlier clinical insight.\n\nThis represents the first implementation of Masimo’s OIRD detection in a hospital monitoring solution, expanding the role of pulse oximetry to surfacing actionable insights.","key_figures":{},"named_entities":{"people":[{"name":"Dr. Basil Matta","role":"Chief Medical Officer at Masimo"}],"products":["Radius VSM","smartSET","Masimo SET","RD SET"],"companies":[{"name":"Masimo","relationship":"subsidiary"},{"name":"Danaher","relationship":"parent company"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-22T12:06:14.415Z","global_importance":30,"audience_relevance":25,"importance_components":{"tickerTier":"mega-cap","eventGravity":"510k_clearance_feature","sectorWeight":"health_care_devices","marketCapAdjustment":-10}},"durationMs":39985,"modelName":"george-droid-qwen-72b"}}